A study has found that Esbriet and Ofev are not cost-effective treatments for idiopathic pulmonary fibrosis (IPF) in the US. Other reports suggest that various treatments, including Esbriet, may have beneficial effects on the condition, such as reducing the risk of irregular heartbeats. The landscape of IPF treatment is evolving, with new approvals, generics, and potential alternatives being explored, amid concerns about rising costs.